经冷冻消融去肾交感神经术(Cryo-RDN)治疗中国未控制高血压患者的有效性与安全性:随机对照试验研究方案
该研究为前瞻性多中心随机假手术对照试验,计划纳入200例经标准药物治疗仍未控制血压的中国高血压患者,在药物标准化后按1:1随机接受冷冻消融去肾交感神经术(Cryo-RDN)或单纯肾动脉造影假手术。主要终点为基线至6个月24小时动态收缩压变化,旨在验证Cryofocus冷冻球囊导管行Cryo-RDN的安全性与有效性。
要点
- 研究纳入标准药物治疗后血压仍未控制的200例中国患者,随机分组前进行药物标准化。
- 主要终点为基线至6个月24小时动态收缩压变化,诊室血压及其他24小时动态血压为次要终点。
- 安全性终点主要包括任何不良事件,研究采用假手术对照设计。
核心结论
- 该研究旨在验证Cryofocus冷冻球囊导管行Cryo-RDN在多重用药仍未控制高血压患者中的安全性与有效性,以期为中国高血压控制提供药物治疗之外的新补充手段。
研究设计与样本
- 前瞻性多中心随机假手术对照试验,计划纳入200例经标准药物治疗仍未控制血压的中国高血压患者。
- 药物标准化后按1:1比例随机分为Cryo-RDN治疗组或单纯肾动脉造影假手术组。
- 使用新型专用冷冻消融球囊导管(Cryofocus,中国)。
- 试验注册号ChiCTR1800017707,于2018年8月10日注册。
主要发现
- 主要终点为基线至6个月24小时动态收缩压的变化。
- 次要终点包括诊室血压及其他24小时动态血压指标。
- 安全性终点主要包括任何不良事件。
关键数值与推荐
- 主要终点:基线至6个月24小时动态收缩压变化。
- 随机化比例:1:1。
- 计划样本量:200例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical data show that due to the limited effects of lifestyle regulation and unsatisfactory drug adherence, only half of the hypertensive population have their blood pressure (BP) under control. In recent years, catheter-based renal denervation (RDN) has been used as a novel approach for treating uncontrolled hypertension. The safety and efficacy of catheter-based RDN have been confirmed by a number of studies and trials in which the participants were all non-Chinese and RDN was conducted via radiofrequency or ultrasound. METHODS/DESIGN: This study is a prospective multicenter randomized sham-controlled trial that aims to investigate the safety and efficacy of cryoablation RDN (cryo-RDN) using a novel dedicated cryoablation balloon catheter (Cryofocus, China). A total of 200 Chinese patients who have uncontrolled hypertension despite standard medical treatment will be enrolled. With drug standardization, eligible participants will be randomized in a 1:1 ratio to undergo cryo-RDN treatment or renal angiography alone as a sham treatment. The primary endpoint is defined as the change in 24-h ambulatory systolic blood pressure from baseline to 6 months. Office BP and other 24-h ambulatory BP are included as secondary endpoints. Safety endpoints primarily include any adverse effects. DISCUSSION: This study was designed to verify the safety and efficacy of cryo-RDN with Cryofocus balloon catheters in uncontrolled hypertensive patients on polypharmacy. The aim is to provide a new way to improve the control of hypertension in China as a complement to drug therapy. TRIAL REGISTRATION: ChiCTR, ChiCTR1800017707. Registered on 10 August 2018.
引用
- Chen H, Ji M, Zhang Y, et al. ReferencesEfficiency and safety of renal denervation via cryoablation (Cryo-RDN) in Chinese patients with uncontrolled hypertension: study protocol for a randomized controlled trial. Trials. 2019. PMID: 31779672. doi:10.1186/s13063-019-3693-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。